Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.98
- Piotroski Score 3.00
- Grade Buy
- Symbol (OPT)
- Company Opthea Limited
- Price $4.19
- Changes Percentage (-1.87%)
- Change -$0.08
- Day Low $4.19
- Day High $4.24
- Year High $5.45
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $14.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.41
- Trailing P/E Ratio -1.04
- Forward P/E Ratio -1.04
- P/E Growth -1.04
- Net Income $-221,049,449
Income Statement
Quarterly
Annual
Latest News of OPT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Clayton Kershaw declines $10 million option to become free agent; Dodgers offer qualifying offer to Teoscar Hernández
Clayton Kershaw declined his $10 million option with the Dodgers but is likely to re-sign. The Dodgers exercised options for Miguel Rojas and Austin Barnes. Teoscar Hernández received a qualifying of...
By CBS News | 16 hours ago -
Twins pick up $1.5 million option on reliever Jorge Alcala for next season
The Minnesota Twins decided to exercise their $1.5 million club option for reliever Jorge Alcala, hoping for a bounce-back season after a mixed performance in 2024. Despite a strong start, Alcala stru...
By CBS News | 17 hours ago -
Nevada's top election official expresses optimism in reporting results quicker
Nevada Secretary of State Francisco Aguilar is optimistic about a more efficient and timely election process for 2022. Anticipating a quick release of results after Election Day, he aims to minimize m...
By The Hill | 17 hours ago
